PETRI DISH PERSPECTIVES

Episode 73: Anew Labs

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Anew Labs, the AI drug discovery company that emerged from one of the most unexpected places in biotech: ByteDance, the parent company of TikTok. Fresh off a $290 million raise at a $1.5 billion valuation, Anew is betting that artificial intelligence can fundamentally change how we discover medicines, not by making existing drug development slightly faster, but by rethinking the entire discovery process from the ground up. We'll break down why ByteDance got into drug discovery in the first place, how Anew's AI platforms work across protein structure prediction, molecular design, and antibody optimization, and what makes its first-in-class small molecule IL-17 program one of the most scientifically ambitious bets in the company's pipeline. We'll also explore the broader competitive landscape, from Anthropic's $400 million acquisition of Coefficient Bio to NVIDIA and Eli Lilly's $1 billion co-innovation lab and what it means that Big Tech is no longer just building tools for pharma, but trying to become the drug company itself. But the biggest question hanging over all of it remains unanswered: can AI actually discover drugs? Not molecules that look promising on a computer. A medicine that works in humans, survives clinical development, gets approved, and changes patient outcomes. We'll dig into why the proof hasn't arrived yet and why Anew is one of the most important tests of that question in the world right now. Because the next breakthrough in medicine may not come from a traditional pharmaceutical company. It may come from an algorithm trained on biology and a team willing to bet everything that the computer got it right. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #AnewLabs #AIDrugDiscovery #ByteDance #Biotech #Biotechnology #Pharma #ArtificialIntelligence #DrugDiscovery #MachineLearning #LifeSciences #Healthcare #Isomorphic #Anthropic #NVIDIA #EliLilly #BispecificAntibody #Immunology #AIinHealthcare #BiotechInnovation #PrecisionMedicine #DrugDevelopment Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 72: Dr. Elliot Justin on S3xual Wearable Health Tech

Send us Fan Mail After a career spent racing against the clock in emergency rooms, Dr. Elliot Justin found himself chasing a very different kind of vital sign, one most men never think to track. Before FirmTech, he built and exited a telemedicine company and a physician staffing group. But it's the wearable ring, designed to quietly monitor erectile function, that's turning heads for an unexpected reason: the data may predict cardiovascular risk years before symptoms ever show up. In this episode, Dr. Justin unpacks how a symptom most men are taught to ignore became one of the most promising early-warning signals in preventive cardiology and what it actually takes to build a hardware company in one of medicine's most stigmatized categories. Check out FirmTech: https://myfirmtech.com/ Use MANEAD15 to receive a discount on FirmTech products. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #HealthTech #DigitalHealth #WearableTech #CardiovascularHealth #MensHealth #PreventiveMedicine #Biotech #HealthInnovation #StartupFounder #MedTech #FirmTech Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

Episode 71: Fate of Pharma M&A

Send us Fan Mail In this episode of Petri Dish Perspectives, we take a step back from individual companies to examine one of the most powerful forces shaping the pharmaceutical industry: M&A, licensing, and the global competition for innovation. We explore how today's pharmaceutical giants were built through decades of consolidation, from Pfizer, GlaxoSmithKline, and Novartis to some of the industry's biggest modern transactions and why dealmaking has increasingly become essential for companies facing massive patent cliffs. But modern pharma is changing. Instead of relying solely on internal R&D or pursuing enormous megamergers, companies are increasingly acquiring targeted biotechs, licensing individual assets, and looking outside traditional innovation hubs for their next blockbuster. We'll also dive into one of the biggest shifts happening in biotech today: the rise of China and Asia as sources of innovative drug development. Western pharmaceutical companies are increasingly licensing molecules and technologies developed outside the U.S. and Europe, even as governments push for supply-chain independence and greater scrutiny of strategic relationships with China. What happens when the pharmaceutical industry is becoming more global while geopolitics is becoming less global? From the biggest deals in pharmaceutical history to the future of cross-border biotech partnerships, this episode asks a bigger question: Has Big Pharma become too dependent on buying innovation rather than building it? And if the best science can increasingly come from anywhere in the world, who will ultimately control the future of medicine? Because pharmaceutical M&A isn't just about buying companies. It's about deciding who gets to own the future of medicine. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #Pharma #Biotech #PharmaMA #BiotechMA #DrugDevelopment #BigPharma #PharmaceuticalIndustry #BiotechInnovation #Healthcare #LifeSciences #BusinessDevelopment #Licensing #PatentCliff #ChinaBiotech #GlobalHealth #Geopolitics #DrugDiscovery #Innovation #HealthcareInnovation Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

August 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for August 2026! This month was defined by major dealmaking, a resurgence in biotech financing, and growing questions about where the global biotech industry is headed. Roche made a $2.5 billion bet on Hanmi, McKesson acquired Precision Medicine Group for $2.25 billion, and the investors behind Metsera quickly returned with Sentivera and a licensing deal worth up to $1.5 billion. Meanwhile, companies including Apnimed, Attovia, and Braveheart kept the IPO market active, suggesting that investor appetite for biotech may be continuing to recover. On the regulatory front, a series of FDA approvals expanded treatment options across HIV, autoimmune disease, cardiovascular disease, cancer, and rare disorders, while three reported deaths in Chinese gene therapy trials sparked renewed debate in Washington about clinical-trial oversight and the FDA's reliance on international data. The bigger story is clear: biotech is becoming increasingly global, capital-intensive, and interconnected, where success depends not only on great science, but also on manufacturing, financing, regulation, and strategic partnerships. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 70: Cellares

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore Cellares, the biotech company trying to solve one of the biggest and least discussed challenges in cell therapy: how do you manufacture these complex, personalized medicines at commercial scale? From CAR-T to gene-edited cell therapies, the science may be advancing rapidly, but manufacturing remains labor-intensive, expensive, and difficult to scale. Cellares believes the answer is automation. We’ll break down the origins of Cellares, the engineering philosophy behind its Cell Shuttle platform, and how the company is attempting to turn cell therapy manufacturing into something closer to an automated pharmaceutical factory. We’ll also explore its partnerships with companies including Bristol Myers Squibb and Cabaletta Bio, the massive investment behind its Smart Factory network, and why pharmaceutical companies have become increasingly interested in automating cell therapy production. But there’s a major twist: Bristol Myers Squibb recently terminated its partnership with Cellares, raising questions about whether the Cell Shuttle is truly ready for commercial-scale manufacturing. We’ll unpack what happened, why manufacturing a clinical-stage therapy isn't necessarily the same as manufacturing a commercial product, and what this could mean for Cellares and the broader future of automated cell therapy. Because the next breakthrough in cell therapy may not be another drug, it may be the factory that finally makes these living medicines scalable. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Cellares #CellTherapy #CAR_T #CAR-T #Biotech #Biotechnology #Pharma #CellTherapyManufacturing #Biomanufacturing #GeneTherapy #DrugDevelopment #LifeSciences #Healthcare #BristolMyersSquibb #CabalettaBio #CellShuttle #Manufacturing #BiotechInnovation #PrecisionMedicine Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 69: Summit Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the remarkable rise of Summit Therapeutics, a biotech that transformed itself from an infectious-disease company into one of the most closely watched oncology companies in the world. At the center of the story is ivonescimab, a next-generation bispecific antibody targeting both PD-1 and VEGF and a drug that could potentially challenge Merck’s blockbuster Keytruda. We’ll dive into Summit’s origins, the company’s dramatic pivot, the story behind its partnership with China’s Akeso, and the science behind why combining immune checkpoint inhibition with VEGF blockade could create a powerful new approach to cancer treatment. We’ll also break down the clinical data in lung cancer, Summit’s growing pipeline, the massive commercial opportunity, and the risks surrounding regulatory approval, clinical durability, and the company’s heavy dependence on a single lead asset. But Summit’s story goes far beyond one cancer drug. Ivonescimab represents a broader shift in how medicines are discovered and commercialized, with innovative assets increasingly emerging from Chinese biotech and being licensed by Western companies for global development. Could Summit become the company that brings a new generation of cancer therapeutics to the world and could ivonescimab really become a challenger to Keytruda? 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #SummitTherapeutics #Ivonescimab #Biotech #Biotechnology #Pharma #Oncology #Cancer #CancerResearch #Immunotherapy #BispecificAntibodies #PrecisionMedicine #DrugDevelopment #ClinicalTrials #Keytruda #Merck #ChineseBiotech #Healthcare #LifeSciences #PharmaceuticalIndustry Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 68: Guardant Health

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Guardant Health, one of the companies leading the shift toward blood-based cancer detection and precision oncology. Founded by genomic scientists Helmy Eltoukhy and AmirAli Talasaz, Guardant is betting that a simple blood draw can reveal critical information about the biology of a tumor, from identifying mutations and guiding treatment to monitoring residual disease and potentially detecting cancer earlier. We'll dive into the science behind liquid biopsy and circulating tumor DNA, Guardant's evolution from Guardant360 into a broader precision-oncology platform, the rise of its Shield colorectal cancer screening test, and the company's growing role in pharmaceutical drug development, real-world evidence, and AI. We'll also explore the promise and major challenges of multi-cancer early detection, including the questions around sensitivity, false positives, reimbursement, and whether detecting cancer earlier actually translates into better outcomes. Because the future of cancer care may not just be about developing better treatments, but about being able to continuously read what cancer is doing inside the body from something as simple as a blood sample. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #GuardantHealth #LiquidBiopsy #Cancer #Oncology #Biotech #Healthcare #PrecisionMedicine #CancerDetection #Genomics #ctDNA #Diagnostics #HealthTech #Pharma #AI #Biotechnology #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 67: Epic Systems

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Epic Systems, the privately held healthcare technology company that has quietly built much of the digital infrastructure behind American healthcare. From Judy Faulkner founding Epic in a Wisconsin basement to becoming the dominant electronic health record platform, Epic has transformed how hospitals, physicians, and patients interact with medical information. We'll dive into Epic's founding story, the evolution of its electronic health record, the rise of MyChart and Cosmos, and how Epic built a massive competitive moat through interoperability, data, workflow integration, and switching costs. We'll also explore its growing role in artificial intelligence, how Epic is embedding AI directly into clinical workflows, and the battle with companies like Oracle Health to control the future of healthcare data. Because the next generation of healthcare won't just be about developing better drugs and devices, it will be about who controls the information infrastructure connecting patients, providers, data, and AI. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #EpicSystems #Healthcare #HealthTech #Biotech #Pharma #AI #ArtificialIntelligence #DigitalHealth #HealthcareInnovation #JudyFaulkner #EHR #HealthData #MedTech #FutureOfHealthcare Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

July 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by AI cementing itself as a core part of drug discovery, with partnerships spanning Anthropic, NVIDIA, Insilico Medicine, and major pharmaceutical companies. At the same time, billion-dollar licensing deals and acquisitions showed that large pharma is aggressively buying innovation rather than building everything internally, particularly in obesity, oncology, radiopharmaceuticals, and gene editing. Regulatory headlines—from the FTC's lawsuit against Hims & Hers to renewed debates around animal testing—reminded us that policy is evolving just as quickly as the science. And with companies like Apnimed and Scribe Therapeutics successfully entering the public markets, investor confidence appears to be returning to biotech. The takeaway is clear: the future of healthcare will be shaped by the convergence of biology, artificial intelligence, precision medicine, and strategic dealmaking—and this month may be remembered as another major step toward that future. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 66: Scribe Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Scribe Therapeutics, one of genome editing's most ambitious companies aiming to move beyond first-generation CRISPR. Rather than accepting the size, delivery, and precision limitations of traditional Cas9, Scribe is redesigning the molecular machinery itself, building smaller, faster, and more versatile X-Editors and pioneering the future of epigenetic regulation. We'll dive into the origins of CRISPR from bacterial immune systems to Nobel-winning breakthroughs, the protein engineering philosophy of co-founder Jennifer Doudna and Benjamin Oakes, and why pharmaceutical giants like Biogen, Eli Lilly, and Sanofi have poured resources into its platform. We'll also break down its pipeline targeting cardiometabolic diseases, rare genetic disorders, and the promise of reversible gene silencing. Because the next era of genetic medicine won't just belong to those who discover biology, but to those who engineer it into safer, more precise cures. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ScribeTherapeutics #Biotech #CRISPR #GeneEditing #ProteinEngineering #Genomics #Genetics #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Cardiometabolic #Epigenetics #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 65: Apogee Therapeutics

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Apogee Therapeutics, one of biotech's newest immunology companies aiming to redefine autoimmune disease through next-generation antibody engineering. Rather than chasing entirely new biological targets, Apogee is focused on improving what already works, developing longer-lasting biologics that could reduce injections from every few weeks to every few months. We'll dive into the evolution of modern immunology, the science behind cytokines and Fc engineering, how Apogee emerged from biotech incubator Paragon Therapeutics, and why investors have poured hundreds of millions of dollars into its vision. We'll also break down its pipeline, including APG777, APG808, and other promising candidates targeting eczema, asthma, inflammatory bowel disease, and beyond. Because sometimes the biggest innovation isn't discovering new biology, it's engineering better medicines for the patients who depend on them. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ApogeeTherapeutics #Biotech #Immunology #AutoimmuneDisease #Biologics #AntibodyEngineering #DrugDevelopment #Pharma #Biotechnology #LifeSciences #Dermatology #Asthma #Inflammation #ProteinEngineering #Healthcare #SciencePodcast #FutureOfMedicine #PrecisionMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 64: Conception Bio

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Conception Bio, one of the most ambitious biotechnology companies working at the intersection of stem cell biology, reproductive medicine, and regenerative science. Their mission? To make eggs from ordinary cells through in vitro gametogenesis (IVG), a breakthrough that could fundamentally change how we think about infertility, fertility preservation, and human reproduction. We'll dive into the science behind IVG, the pioneering research that made the field possible, the founders' vision, and why investors believe reproductive biology could become one of biotech's next major frontiers. We'll also discuss the enormous technical hurdles, ethical questions, and potential applications for cancer survivors, age-related infertility, LGBTQ+ family building, and beyond. Because the next revolution in medicine may not be about curing disease, it may be about creating life's very first cell. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #ConceptionBio #Fertility #IVF #StemCells #RegenerativeMedicine #Biotech #ReproductiveBiology #InVitroGametogenesis #IVG #DrugDiscovery #Healthcare #LifeSciences #DevelopmentalBiology #PrecisionMedicine #WomenInScience #Biotechnology #SciencePodcast #FutureOfMedicine #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 63: Enveda Biosciences

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Enveda Biosciences, one of the most exciting AI-native biotech companies redefining how drugs are discovered. While most pharmaceutical companies build vast synthetic chemical libraries, Enveda is using artificial intelligence, metabolomics, and mass spectrometry to unlock the world's largest and largely untapped chemical library: nature. We'll trace the history of natural product drug discovery, from penicillin and paclitaxel to the AI revolution, dive into founder Viswa Colluru's vision of creating a searchable map of nature's chemistry, and explore how Enveda's platform is transforming plants, fungi, and microbes into tomorrow's medicines. We'll also discuss the company's growing clinical pipeline, why investors have poured hundreds of millions into the platform, and whether AI can finally solve one of drug discovery's oldest challenges. Because sometimes, the future of medicine isn't invented, it evolves. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Enveda #ArtificialIntelligence #AI #DrugDiscovery #Biotech #NaturalProducts #MachineLearning #Metabolomics #Pharmaceuticals #Healthcare #PrecisionMedicine #MedicinalChemistry #LifeSciences #Biotechnology #Innovation #ClinicalResearch #DrugDevelopment #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 62: Isomorphic Labs

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore the story of Isomorphic Labs, Alphabet's ambitious drug discovery company born out of DeepMind's groundbreaking work on AlphaFold. From solving one of biology's greatest mysteries, protein folding, to building an AI-native pharmaceutical company, Isomorphic Labs is attempting to fundamentally change how medicines are discovered. We'll dive into the origins of AlphaFold, the scientific vision of Nobel Prize-winning CEO Demis Hassabis, how AI is reshaping medicinal chemistry, and why pharmaceutical giants like Novartis and Eli Lilly are investing billions in AI-powered drug discovery partnerships. We'll also discuss the promise, challenges, and future of foundation models in biology, and whether AI can truly accelerate the journey from molecule to medicine. Because the next blockbuster drug may not be discovered by chance, it may be designed by an algorithm. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #IsomorphicLabs #DeepMind #AlphaFold #ArtificialIntelligence #AI #DrugDiscovery #Biotech #Healthcare #PrecisionMedicine #Pharmaceuticals #MachineLearning #ProteinFolding #DemisHassabis #NobelPrize #MedicinalChemistry #LifeSciences #Biology #Google #Alphabet #EliLilly #Novartis #FutureOfMedicine #SciencePodcast #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

June 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for June 2026! This month was dominated by a relentless wave of strategic consolidation and "barbell" deal-making, as Big Pharma aggressively swapped capital for late-stage security while doubling down on early-stage, high-tech innovation. From AbbVie’s multi-billion-dollar immunology power play to a flurry of high-stakes partnerships involving AI-native drug discovery and novel protein-degradation platforms, the industry spent June 2026 signaling a clear preference for integrated precision, prioritizing assets that can bypass traditional resistance mechanisms and redefine standards of care in oncology and metabolic disease. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 61: Danaher

Send us Fan Mail In this episode of Petri Dish Perspectives, we explore how two brothers transformed a small industrial holding company into one of the most influential life sciences organizations in history. We dive into the origins of the Danaher Business System (DBS), the acquisition strategy that reshaped biotechnology, the landmark purchases of Beckman Coulter, Pall, and Cytiva, and why Danaher became one of the biggest winners of the COVID-19 era. While biotech headlines focus on breakthrough drugs and billion-dollar acquisitions, Danaher quietly supplies the tools, diagnostics, manufacturing systems, and technologies that power modern medicine. From sequencing cancer genomes and producing monoclonal antibodies to manufacturing gene therapies and vaccines, Danaher sits behind the scenes enabling scientific innovation across the globe. We'll also discuss the leadership of Larry Culp, the company's role in the rise of biologics, gene therapies, and precision medicine, and the lessons Danaher offers about building value through infrastructure rather than blockbuster products. Because sometimes the companies changing healthcare aren't the ones discovering the drugs, they're the ones making discovery possible. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #Danaher #Biotech #LifeSciences #Healthcare #Biopharma #Cytiva #PallCorporation #BeckmanCoulter #Diagnostics #GeneTherapy #CellTherapy #Biologics #Pharmaceuticals #DrugDevelopment #PrecisionMedicine #LaboratoryScience #LarryCulp #BusinessPodcast #BiotechPodcast #HealthcareInnovation #Investing #Science #CorporateHistory #HealthcareBusiness Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 60: Hims & Hers

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the rise of Hims & Hers Health, the telehealth company that transformed direct-to-consumer healthcare and challenged traditional medicine. Founded in 2017 by Andrew Dudum, Hims & Hers built a billion-dollar business by removing the stigma around men's and women's health, using digital-first care, subscription medicine, and aggressive branding to reach millions of patients. We explore the company's founding story, rapid growth, SPAC-era public debut, expansion into mental health, dermatology, weight loss, and primary care, as well as the controversies surrounding compounded GLP-1 medications, regulatory scrutiny, and the broader debate around the future of telemedicine. From Silicon Valley startup to healthcare disruptor, Hims & Hers offers a fascinating case study in consumerization, accessibility, and the changing relationship between patients and providers. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #PetriDishPerspectives #HimsAndHers #Telehealth #DigitalHealth #HealthcareInnovation #GLP1 #WeightLossDrugs #Biotech #HealthcareBusiness #StartupStories #PublicMarkets #HealthcareTechnology #DirectToConsumer #Pharma #HealthTech #BusinessPodcast #AndrewDudum #Medicine #HealthcareDisruption #BiotechPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 59: Illumina

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable story of Illumina, from a small sequencing startup born during the Human Genome Project era to the company that transformed DNA sequencing from a billion-dollar scientific challenge into a routine laboratory tool. We explore how Illumina's sequencing-by-synthesis technology became the gold standard for genomics, enabling everything from cancer research and rare disease diagnosis to population-scale genetic studies. You'll hear how the company built an empire around the idea that reading DNA would become as essential to medicine as blood tests and imaging scans. We also unpack the major milestones that shaped Illumina's rise: the acquisition of Solexa, the launch of revolutionary sequencing platforms, the race to the "$1,000 genome," and the company's ambitious vision for detecting cancer through blood tests. Along the way, we'll examine the controversial Grail acquisition, regulatory battles with the European Union, leadership shakeups, and the strategic decisions that defined one of biotech's most influential companies. From the Human Genome Project to multi-billion-dollar cancer screening ambitions, this is the story of the company that made genomics mainstream. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #Illumina #Genomics #DNASequencing #HumanGenomeProject #Grail #CancerDetection #LiquidBiopsy #Biotech #Biotechnology #PrecisionMedicine #GeneticTesting #NextGenerationSequencing #NGS #LifeSciences #HealthcareInnovation #MolecularBiology #CancerResearch #BioTechPodcast #PetriDishPerspectives Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

Episode 58: UnitedHealthcare

Send us Fan Mail In this episode of Petri Dish Perspectives, we dive into the remarkable rise of UnitedHealthcare and its parent company, UnitedHealth Group. From its origins in the 1970s managed care movement to becoming a healthcare empire worth hundreds of billions of dollars, UnitedHealthcare has fundamentally transformed how healthcare is financed, delivered, and managed in the United States. We explore the company's founding story, the leadership of industry-defining executives, the creation of Optum, and the acquisition strategy that turned UnitedHealth into far more than an insurance company. We also unpack the controversies surrounding prior authorizations, claim denials, Medicare Advantage investigations, antitrust concerns, and the growing public frustration with the American healthcare system. Finally, we examine one of the most shocking moments in modern corporate history: the assassination of CEO Brian Thompson in 2024, the national conversation it sparked, and what it revealed about the growing tension between healthcare corporations and the patients they serve. This is a story about scale, innovation, power, controversy, and the future of healthcare itself. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes every Thursday! https://linktr.ee/maneadkhin #UnitedHealthcare #UnitedHealthGroup #Optum #Healthcare #HealthInsurance #MedicareAdvantage #HealthcareInnovation #HealthcareBusiness #Biotech #Pharma #HealthTech #BrianThompson #CorporateStrategy #PetriDishPerspectives #HealthcarePolicy #DigitalHealth #ValueBasedCare #ManagedCare #HealthcareEconomics #BusinessPodcast Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters

May 2026: Biotech & Pharma NEWS Roundup

Send us Fan Mail Welcome to your essential overview of the global biotech and pharmaceutical landscape for May 2026! This month was dominated by a wave of aggressive cross-border M&A and strategic capital deployment, as pharma giants pivoted to secure the next generation of oncology, metabolic, and infectious disease assets. From high-stakes acquisitions aimed at building comprehensive "acute care" architectures to massive investments in generative AI-driven discovery engines, the industry has clearly shifted toward a model of integrated precision, prioritizing both the speed of research and the consolidation of complex manufacturing infrastructure. 🎧 Listen now, stay curious, and don’t forget to subscribe for new episodes! https://linktr.ee/maneadkhin #PetriDishPerspectives #BiotechNews #PharmaNews Support the show © 2026 The Perspective Bureau LLC. All rights reserved.

• Transcript
• Chapters